Adele C. Oliva
Adele Oliva has been a healthcare investor for over 20 years and focuses on commercial stage medical technology, healthcare service, and specialty pharmaceutical investments. Adele co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing and the firm has since raised two funds and has over $500 million under management. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.
Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.
Adele has served on the board of Ascent Healthcare Solutions, EKR Therapeutics, ESP Pharma, Esprit Pharma, Genoptix, Precision Dermatology, Prometheus Labs, and SkinMedica. She currently serves on the boards of Colorescience, Encore Dermatology, Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.